Movva N, Girguis M, Bylsma L, Saleem N, Grasic K, Suh M, Pastula S, Frankenfeld C. 2025. Systematic literature review of glucagon-like peptide 1 (GLP-1) receptor agonist use among type 2 diabetes in the United States. PROSPERO 2025:CRD4202564618. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025646418.
Abstract
Review Objectives: 1) In the published literature, what is the prevalence and prescription patterns of GLP-1 receptor agonist use among real-world T2D patients in the US? 2) In the published literature, what are the sociodemographic and clinical characteristics of real-world GLP-1 users with T2D in the US? 3) In the published literature, what is the long and short term real-world effectiveness of GLP-1 therapy among T2D patients in the US (including weight loss, glycemic control, T2DM remission)? 4) In the published literature, how is the patient journey, including initiation, access, adherence, persistence, and discontinuation, described for real-world GLP-1 users with T2D in the US? 5) In the published literature, what are the patient-reported outcomes described for real-world T2D patients in the US on GLP-1 therapies? 6) In the published literature, what are the safety outcomes described for real-world T2D patients in the US on GLP-1 therapies?